TOP TEN perturbations for 39249_at (Homo sapiens)
Organism: Homo sapiens
Gene: 39249_at
Selected probe(set): 39248_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 39249_at (39248_at) across 6674 perturbations tested by GENEVESTIGATOR:
Langerhans cell histiocytosis study 2 (multisystem) / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):-10.190409Number of Samples:2 / 10
Experimental | Langerhans cell histiocytosis study 2 (multisystem) |
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with multifocal, multisystem (disseminated) disease. Both patients received chemotherapy. Sites of LCH lesions: subj.ID:1 (skin, lungs, multiple skull, mastoid, gingiva), subj.ID:13 (mandible, skull, vertebrae, recurrent orbit, liver, spleen, pituitary gland). | |
Control | normal epidermal Langerhans cell sample |
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):7.5559845Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
melanoma study 34 (metastatic) / melanoma study 34 (in situ)
Relative Expression (log2-ratio):-6.8587313Number of Samples:40 / 2
Experimental | melanoma study 34 (metastatic) |
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain). | |
Control | melanoma study 34 (in situ) |
Tumor tissue from the skin of patients with melanoma in situ. |
melanoma study 34 (metastatic) / normal skin tissue
Relative Expression (log2-ratio):-6.4268103Number of Samples:40 / 4
Experimental | melanoma study 34 (metastatic) |
Metastatic tumor tissue sample obtained from the patients with metastatic malignant melanoma of the skin. Metastatic samples composed of 22 macroscopic lymph node metastases, 16 subcutaneous metastases and 2 solid organ metastases (adrenal and brain). | |
Control | normal skin tissue |
Normal skin tissue. |
Langerhans cell histiocytosis study 2 (unifocal) / normal epidermal Langerhans cell sample
Relative Expression (log2-ratio):-6.295781Number of Samples:8 / 10
Experimental | Langerhans cell histiocytosis study 2 (unifocal) |
Langerhans cell histiocytes (LCH, CD207+) samples isolated from LCH lesions of patients with unifocal, single system disease (bone lesion). | |
Control | normal epidermal Langerhans cell sample |
Normal epidermal Langerhans cells (CD207+) were isolated from skin of children donors (age < 18 years). The Langerhans cells were isolated from presumably healthy tissue. |
IL-4; GM-CSF study 1 (late) / untreated monocyte sample
Relative Expression (log2-ratio):6.2406397Number of Samples:6 / 12
Experimental | IL-4; GM-CSF study 1 (late) |
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 5 days. Cytokine treatment was repeated at day 3. | |
Control | untreated monocyte sample |
Freshly isolated human monocytes from healthy donors. |
PMA study 7 (12h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):5.942173Number of Samples:2 / 12
Experimental | PMA study 7 (12h) |
HepG2 cells exposed to 500nM phorbol-12-myristat-13-acetate [(PMA ortetradecanoyl phorbol acetate (TPA)] in DMSO solvent for 12 hours. ATC code:--- | |
Control | vehicle (DMSO) treated HepG2 cell sample |
HepG2 cells exposed to DMSO solvent for 12 hours. |
stem cell differentiation study 41 (hES-T3 EB) / undifferentiated hES-T3 cell sample
Relative Expression (log2-ratio):5.940277Number of Samples:2 / 3
Experimental | stem cell differentiation study 41 (hES-T3 EB) |
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype. | |
Control | undifferentiated hES-T3 cell sample |
Undifferentiated human embryonic stem cells T3. |
diazinon study 1 (24h) / vehicle (DMSO) treated HepG2 cell sample
Relative Expression (log2-ratio):5.918132Number of Samples:3 / 7
Experimental | diazinon study 1 (24h) |
HepG2 cells exposed to 250μM diazinon in DMSO solvent for 24 hours. ATCvet code: | |
Control | vehicle (DMSO) treated HepG2 cell sample |
HepG2 cells exposed to DMSO solvent for 24 hours. |
OPM-1 / MM1.S
Relative Expression (log2-ratio):-5.7396507Number of Samples:4 / 4
Experimental | OPM-1 |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-resistant. Synonyms:OPM1 Cellosaurus code: | |
Control | MM1.S |
Human primary cancer cell line derived from the peripheral blood of a patient with multiple myeloma. Dexamethasone-sensitive. Parental cell line:: MM.1 Synonyms:MM.1S; MM1-S; MM-1S; MM1S Cellosaurus code: |